sanofi december letter to shareholders , page-7

Great summary Curly, Also add in the fact that UNS is trying to get a portion of the revenue saved by these multi billion $$$$$ drugs. So if they have a sales now of $2bn and expect to loose 60% to generics ($1.2Bn) if we can by the use of our product protect say $400M of those lost sales then we get a cut of the action. If we get 5% of $12.4bn thats a hell of a lot.

Back to cost cutting, last time I ran total sales of prefills against revenue it was $17 USD per item (syringe plus drugs). Our 80c device is a very small % of costs and is a major driver of value due safety and disposal problems from non integrated devices. In my humble opinion it makes money to use our product..

They will still try and screw us .......... LOL